CBER Director Peter Marks (Susan Walsh/Pool via AP Images)

Pe­ter Marks sin­gle-hand­ed­ly ap­proved Sarep­ta’s gene ther­a­py — what does that mean for every­one else?

Is Sarep­ta spe­cial? Or has the FDA set a new prece­dent for how it ap­proach­es treat­ments for dev­as­tat­ing dis­eases with few op­tions?

On Thurs­day, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.